These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 15291670

  • 1. Comments on cost analysis of risperidone versus olanzapine.
    Duggal HS, Gandotra G.
    J Clin Psychiatry; 2004 Jun; 65(6):879-80; author reply 880. PubMed ID: 15291670
    [No Abstract] [Full Text] [Related]

  • 2. Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.
    Lucey JV, Libretto SE.
    Ir J Med Sci; 2003 Jun; 172(4):195-201. PubMed ID: 15029989
    [Abstract] [Full Text] [Related]

  • 3. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT.
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [Abstract] [Full Text] [Related]

  • 4. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
    Taylor DM, Wright T, Libretto SE, Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator Group.
    J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
    [Abstract] [Full Text] [Related]

  • 5. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
    Bounthavong M, Okamoto MP.
    J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.
    Hargreaves WA, Gibson PJ.
    CNS Drugs; 2005 Jun; 19(5):393-410. PubMed ID: 15907151
    [Abstract] [Full Text] [Related]

  • 7. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL.
    Value Health; 2004 Jun; 7(1):22-35. PubMed ID: 14720128
    [Abstract] [Full Text] [Related]

  • 8. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
    Yu W, Ren XS, Lee AF, Herz L, Huang YH, Kazis LE.
    Pharmacoeconomics; 2006 Jun; 24(12):1233-48. PubMed ID: 17129077
    [Abstract] [Full Text] [Related]

  • 9. Cost evaluation of risperidone compared with olanzapine.
    Byerly MJ, Weber M, Brooks D, Casey SB, Elliot S, Hawkins J.
    Psychiatr Serv; 2003 May; 54(5):742-4. PubMed ID: 12719509
    [Abstract] [Full Text] [Related]

  • 10. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK, Tarn YH, Wang TY, Liu CY, Laio YC, Chou YH, Lee SM, Chen CC.
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [Abstract] [Full Text] [Related]

  • 11. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.
    Kelly DL, Nelson MW, Love RC, Yu Y, Conley RR.
    Psychiatr Serv; 2001 May; 52(5):676-8. PubMed ID: 11331805
    [Abstract] [Full Text] [Related]

  • 12. Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model".
    Clewell JD, Baker RW.
    Value Health; 2005 May; 8(2):175-6. PubMed ID: 15804326
    [No Abstract] [Full Text] [Related]

  • 13. A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia.
    Cooper D, Moisan J, Abdous B, Grégoire JP.
    Can J Clin Pharmacol; 2008 May; 15(3):e385-97. PubMed ID: 18953083
    [Abstract] [Full Text] [Related]

  • 14. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.
    Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A.
    Schizophr Bull; 2008 Nov; 34(6):1163-71. PubMed ID: 18156640
    [Abstract] [Full Text] [Related]

  • 15. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
    Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL.
    Pharmacoeconomics; 2003 Nov; 21(10):683-97. PubMed ID: 12828491
    [Abstract] [Full Text] [Related]

  • 16. Assessing cost-effectiveness of drug interventions for schizophrenia.
    Magnus A, Carr V, Mihalopoulos C, Carter R, Vos T.
    Aust N Z J Psychiatry; 2005 Nov; 39(1-2):44-54. PubMed ID: 15660705
    [Abstract] [Full Text] [Related]

  • 17. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.
    Zhao Z.
    Manag Care Interface; 2002 Feb; 15(2):75-81. PubMed ID: 11875967
    [Abstract] [Full Text] [Related]

  • 18. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.
    Zhao Z.
    Curr Med Res Opin; 2004 Jul; 20(7):1039-48. PubMed ID: 15265249
    [Abstract] [Full Text] [Related]

  • 19. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
    Lindner LM, Marasciulo AC, Farias MR, Grohs GE.
    Rev Saude Publica; 2009 Aug; 43 Suppl 1():62-9. PubMed ID: 19669066
    [Abstract] [Full Text] [Related]

  • 20. Health care costs for schizophrenia patients started on olanzapine versus risperidone.
    Russo PA, Smith MW, Namjoshi M.
    Am J Health Syst Pharm; 2005 Mar 15; 62(6):610-5. PubMed ID: 15757882
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.